Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Corbus Pharmaceuticals Holdings, Inc., today announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe (“Western study”) of CRB-701 (SYS6002) has been released. Read more >>

Share this post